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Perspective
Compassionate use of experimental
therapies: who should decide?
Patricia J Zettler
In addition to being an example of
unsubstantiated hype about regenerative
medicine, the controversy around the Italy-
based Stamina Foundation’s unproven
stem cell therapy represents another chap-
ter in a continuing debate about how to
balance patients’ requests for early access
to experimental medicines with require-
ments for demonstrating safety and
effectiveness. Compassionate use of the
Stamina therapy arguably should not have
been permitted under Italy’s laws, but
public pressure was intense and judges
ultimately granted access. One lesson from
these events is that expert regulatory
agencies may be the institutions most
competent to make compassionate use
decisions and that policies should include
more specific criteria for authorizing
compassionate use. But even where regula-
tory agencies make decisions based on
clear rules, difficult questions will arise.
E arlier this year, a 6-year saga about amuch hyped stem cell-based treatmentfor neurological diseases came to a
close when criminal charges against the
founder of the Italy-based Stamina Founda-
tion, including charges of fraud, were
resolved through a plea bargain. Founded in
2009, the Stamina Foundation claimed that
it was transforming mesenchymal stem cells
from bone marrow into neural stem cells
and that injections with these cells would be
a treatment for various neurodegenerative
diseases, including Parkinson’s disease and
muscular dystrophy (Cattaneo & Corbellini,
2014). Their claims were scientifically
implausible and unsupported by published
evidence, but, understandably, convinced
numerous people with devastating diseases
and few treatment options to seek access to
the therapy (Rial-Sebbag & Blasimme, 2014).
Before the “compassionate use” of Stamina’s
“therapies” was stopped, more than 100
patients had received it, with many paying
thousands of Euros (Rial-Sebbag & Blasimme,
2014).
......................................................
“it is critical for public health
that the law requires that new
medicines are shown to be safe
and effective before they can be
marketed.”
......................................................
The popular demand for the Stamina
stem cell therapy, despite the lack of any
evidence supporting its safety or efficacy,
serves as a vivid example of both the appeal
and the dangers of making unsubstantiated
claims about regenerative medicine. Beyond
this, the Stamina controversy represents
another chapter in a longstanding debate
about how to balance seriously ill patients’
desire to use experimental medicines—what
the European Medicines Agency (EMA) calls
“compassionate use,” and the US Food and
Drug Administration (FDA) calls “expanded
access”—with legal requirements for
demonstrating safety and effectiveness
before clinicians can use these medicines
(Zettler & Greely, 2014). On the one hand, it
is critical for public health that the law
requires that new medicines are shown to be
safe and effective before they can be
marketed. On the other hand, seriously ill
patients may not have the time to wait for
months or years until a therapy has been
approved. This tension gives rise to compas-
sionate use controversies.
Patients have repeatedly been enticed to
seek purportedly life-saving treatments that
were unsupported by scientific evidence, or
even fraudulent. Desperate cancer patients
have been targeted by sellers of “alternative”
or quack drugs such as laetrile (Lerner,
1984), vitamin formulations, and many
others. But many patients’ access requests
have involved medicines that were
supported by some, albeit not conclusive,
evidence, or medicines that were later
approved for the condition. During the
1980s, AIDS patients mounted a highly
publicized effort to gain early access to
experimental antiretroviral drugs. In another
well-publicized controversy in the 2000s, an
advocacy group called the Abigail Alliance
unsuccessfully sued the FDA for broader
compassionate use after the founder’s
daughter was unable to enroll in clinical
trials of two unapproved medicines for
cancer, including a trial of a drug that was
later approved for her particular diagnosis.
More recently, compassionate use questions
resurfaced in response to the Ebola
epidemic, prompting an advisory panel to
the World Health Organization to recom-
mend that, in certain circumstances, it
would be appropriate to treat patients with
unapproved medicines (Hantel & Olopade,
2015).
The European Union (EU) and the USA,
the world’s largest pharmaceutical markets,
have developed laws and policies that, in
limited circumstances, permit access to
experimental medicines and therapies before
approval and outside of clinical trials. Their
policies are based on similar principles and
permit access only for terminally or seri-
ously ill patients who do not have satisfac-
tory therapeutic options among legally
marketed treatments (European Medicines
Agency, 2007; guideline on compassionate
use of medicinal products, pursuant to
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Article 83 of Regulation (EC) No 726/2004)
(U.S. Food and Drug Administration, 2014;
Expanded Access to Investigational Drugs
for Treatment Use, 74 Federal Register
40900–40945). Likewise, both the European
Court of Human Rights and US courts have
rejected terminally and seriously ill patients’
claims that they possess an unfettered right
to access unproven medicines (Hristozov
and others v. Bulgaria, 2013, nos. 47039/
11 and 358/12; http://hudoc.echr.coe.int/
sites/eng/pages/search.aspx?i=001-114492)
(Durisotto v. Italy, 2014, no. 62804/13; http://
hudoc.echr.coe.int/sites/eng/pages/search.
aspx?i=001-148030) (Shah & Zettler, 2010).
Although the general principles are simi-
lar, how these are implemented differs
among EU member states, and between the
EU and the USA (European Medicines
Agency, 2007; guideline on compassionate
use of medicinal products, pursuant to Article
83 of Regulation (EC) No 726/2004) (U.S.
Food and Drug Administration, 2014;
Expanded Access to Investigational Drugs for
Treatment Use, 74 Federal Register 40900–
40945) (Whitfield et al, 2010). Nonetheless,
under many regulatory schemes—including
Italy’s—access to Stamina’s stem cell treat-
ments should not have been granted. Italy
permits compassionate use of experimental
cell therapies only when there are some
published data justifying their use (Italian
Ministry of Health, Decree December 5,
2006, published in the Official Journal
March 9, 2007). In 2012, the Agenzia Ital-
iana del Farmaco (AIFA, the Italian medici-
nes agency) determined that this condition,
among others, was not met and denied
compassionate use. However, public pres-
sure for access to the therapy was intense.
Many Italian courts granted patients’ access
to it and Italian politicians provided funding
for a clinical trial.
......................................................
“who makes decisions about
patients’ access requests can
play an important role in the
outcome of those requests.”
......................................................
The Stamina stem cell controversy is not
an indictment of Italy’s formal policy for
compassionate use. After all, it was judges
and politicians, not the AIFA, who decided
to grant patients’ access to the Stamina stem
cell therapy despite the lack of evidence
supporting its use. Instead, the controversy
shows that who makes decisions about
patients’ access requests can play an impor-
tant role in the outcome of those requests.
When patients’ requests are sympathetic, as
they often are, and the public’s hopes for an
experimental medicine are high, it may be
difficult for judges and politicians to deny
requests even if they lack scientific merit.
While expert regulatory agencies—such as
the AIFA, the EMA, and the FDA—are not
immune to such difficulties, they may be
better situated than judges or politicians to
determine whether the evidence suggests
that a medicine, although unproven, is
promising enough that granting access for
particular patients is appropriate.
This, however, is not to say that formal
expanded access policies are irrelevant or
cannot be improved. In the 2000s, the FDA’s
expanded access rules were criticized for
being vague and inconsistently applied. In
response, the FDA revised its rules in 2009
to include specific criteria and requirements
that must be met to authorize access, such
as that the potential risks of the experimen-
tal medicine are reasonable in the context of
the patient’s disease (U.S. Food and Drug
Administration, 2009; Expanded Access to
Investigational Drugs for Treatment Use, 74
Federal Register 40900-40945). Likewise, it
may be useful to clarify the standard for
access to experimental medicines, including
cell therapies, in EU member states by
adding more specific criteria and require-
ments to help ensure that patients, compa-
nies that are asked to supply the medicines,
and regulators share an understanding about
which access requests are likely to be
granted.
But even where regulatory agencies make
decisions based on clear rules, those rules
might not address all aspects of compassion-
ate use. For example, the FDA authorizes
the vast majority of the requests that it
receives, but it cannot compel a company to
provide a medicine; the decision about
whether to provide a drug often ultimately
falls to the company, which may have little
guidance about how to prioritize access
requests if, for example, the supply of the
drug is limited. To address this dilemma,
Johnson & Johnson recently created a panel
of doctors, bioethicists, and patient repre-
sentatives to advise it in its access decisions
(Rockoff, 2015). If this proves useful, more
companies may follow suit, or regulatory
agencies may consider providing companies
such guidance themselves.
Moreover, improving communication
about experimental medicines may be of
particular relevance for regenerative medi-
cine because of the public’s high hopes for
the field (Kamenova & Caulfield, 2015).
Indeed, a February 2015 report, issued in
the wake of the Stamina controversy and
spearheaded by Italian scientist and senator
Elena Cattaneo, recommended that Italy
provides its media with guidelines on
communicating scientific information. But
depending on the jurisdiction, there will be
limits on how extensively the government
can steer or influence media coverage about
experimental medicines, because of constitu-
tional protections for speech in democratic
societies.
......................................................
“social media may play an
increasingly important role in
the debates.”
......................................................
The debate about expanded access/
compassionate use is likely to continue for
the foreseeable future, and new challenges
will arise. More patients seem to be request-
ing expanded access—the FDA received
almost double the number of access
requests in 2014 as it did in 2013—and
social media may play an increasingly
important role in the debates as it gives
patients and their advocates an effective tool
to directly and publicly reach companies
and regulators. Efforts to improve the
compassionate use process outside of regu-
latory structures by, for example, improving
communication about unproven medicines
or establishing corporate advisory panels
may prove useful in and of themselves, but
perhaps more importantly, will help to
identify new directions for refining laws and
policies.
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